Praxis Precision Medicines, Inc. — Director's Dealing 2021

Feb 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Praxis Precision Medicines, Inc. (PRAX)
CIK: 0001689548
Period of Report: 2021-02-12

Reporting Person: Ravina Bernard (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-12	Common Stock	A	24512	—	Acquired	80533	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-12	Stock Option (Right to Buy)	$52.53	A	65800	Acquired	2031-02-12	Common Stock (65800.0)	Direct

Footnotes

F1: Dr. Ravina was awarded 24,512 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units vest over a four-year period, with 10,412 shares vesting on February 12, 2022, 4,700 shares vesting on February 12, 2023, 4,700 shares vesting on February 12, 2024 and 4,700 shares vesting on February 12, 2025. The restricted stock units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

F2: The shares underlying this stock option vest over a four-year period, with 25% vesting on the one-year anniversary of the vesting commencement date of February 12, 2021 and the remaining 75% vesting in 36 equal monthly installments following such first anniversary, subject to the reporting person's continued service through each vesting date.